Mohammad Zulfiqar, Afessa Bekele, Finkielman Javier D
Department of Cardiothoracic Anesthesiology, The Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Crit Care. 2006;10(4):R105. doi: 10.1186/cc4979.
Etomidate blocks adrenocortical synthesis when it is administered intravenously as a continuous infusion or a single bolus. The influence of etomidate administration on the incidence of relative adrenal insufficiency in patients with septic shock has not been formally investigated. The objective of this study was to determine the incidence of relative adrenal insufficiency in patients with septic shock after etomidate administration compared with patients with septic shock who did not receive etomidate.
In this retrospective study, 152 adults with septic shock who had a consyntropin stimulation test between March 2002 and August 2003 in a tertiary medical center were included. Relative adrenal insufficiency was defined as a rise in serum cortisol <or= 9 microg/dl after the administration of 250 microg of consyntropin. Patients were divided into those who did and those who did not receive etomidate before the stimulation test. The proportion of patients with relative adrenal insufficiency in these two groups was compared using Fischer's exact test. A P of value < 0.05 was considered statistically significant.
The mean age of the patients was 64 years, 59% of patients were male, 97% of patients were white and their hospital mortality rate was 57%. Thirty-eight patients (25%) received etomidate before the cosyntropin stimulation test, and the median (interquartile range) time interval between the administration of the drug and the test was 7 (4-10) hours. The incidence of relative adrenal insufficiency was 76% in the patients who received etomidate compared with 51% in the patients who did not (P = 0.0077).
The incidence of relative adrenal insufficiency in patients with septic shock is increased when the stimulation test is performed after the administration of etomidate.
依托咪酯静脉持续输注或单次大剂量给药时会阻断肾上腺皮质合成。依托咪酯给药对感染性休克患者相对肾上腺功能不全发生率的影响尚未得到正式研究。本研究的目的是确定与未接受依托咪酯的感染性休克患者相比,接受依托咪酯治疗的感染性休克患者相对肾上腺功能不全的发生率。
在这项回顾性研究中,纳入了2002年3月至2003年8月在一家三级医疗中心接受促肾上腺皮质激素刺激试验的152例成年感染性休克患者。相对肾上腺功能不全定义为静脉注射250μg促肾上腺皮质激素后血清皮质醇升高≤9μg/dl。患者被分为在刺激试验前接受和未接受依托咪酯的两组。使用Fisher精确检验比较这两组中相对肾上腺功能不全患者的比例。P值<0.05被认为具有统计学意义。
患者的平均年龄为64岁,59%为男性,97%为白人,医院死亡率为57%。38例患者(25%)在促肾上腺皮质激素刺激试验前接受了依托咪酯,给药与试验之间的中位(四分位间距)时间间隔为7(4 - 10)小时。接受依托咪酯的患者相对肾上腺功能不全的发生率为76%,而未接受依托咪酯的患者为51%(P = 0.0077)。
在依托咪酯给药后进行刺激试验时,感染性休克患者相对肾上腺功能不全的发生率会增加。